31 results on '"Vij R"'
Search Results
2. An ongoing multinational observational study in multiple myeloma (PREAMBLE): Preliminary report on patient survival: 270
3. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma
4. A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma
5. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes
6. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
7. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
8. OPEN: Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
9. IV plerixafor combined with G-CSF is highly effective for stem cell mobilization in lymphoma patients undergoing autologous stem cell collection: O193
10. Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials: 42
11. A phase II study (PX-171–003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM): 14
12. A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
13. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
14. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature
15. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG
16. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
17. Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma: A573
18. Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004): A493
19. Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003): A377
20. Phase II Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004): A378
21. Phase Ib Study of Elotuzumab (HuLuc63) in Combination with Lenalidomide in Relapsed Multiple Myeloma: A129
22. Solitary Plasmacytoma: A SEER Database Analysis of Survival: A089
23. Plasma Cell Leukemia: A SEER Database Analysis: A090
24. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma
25. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ≥10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients
26. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone
27. West Nile Virus encephalopathy in an allogeneic stem cell transplant recipient: use of quantitative PCR for diagnosis and assessment of viral clearance
28. Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma
29. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes
30. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
31. Effect of HPC and water concentration on the evolution of size, aggregation and crystallization of sol-gel nano zirconia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.